Application of NKG7 detection reagent in preparation of kit for predicting tumor immunotherapy curative effect and / or adverse reaction

Through the kit for detecting NKG7, the problems of low efficacy and complex adverse reactions in the treatment of immune checkpoint inhibitors are solved, and accurate prediction and adverse reaction monitoring of tumor immunotherapy are achieved, improving the treatment effect and safety.

CN118980818APending Publication Date: 2024-11-19THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411046131.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing immune checkpoint inhibitors are inefficient in the treatment of tumor patients and the immune-related adverse reactions triggered by complexity. The existing predictive markers are limited and dynamic monitoring is not possible, resulting in interruption of treatment and difficult to predict adverse reactions.

Method used

Develop a kit for detecting NKG7 to predict the efficacy and adverse reactions of immunotherapy by detecting the expression of soluble NKG7 in tumor tissues, plasma, and exosomes, especially through the ratio of peripheral blood NKG7 high CD8+ T cells to distinguish different types of immunity. Treatment-related adverse reactions.

Benefits of technology

It has achieved accurate prediction of the efficacy and adverse reactions of tumor immunotherapy, which is earlier than clinical imaging evaluation, has good practical application value, and has improved the efficacy and safety of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118980818A_ABST
    Figure CN118980818A_ABST
Patent Text Reader

Abstract

The invention relates to application of a reagent for detecting NKG7 in preparation of a kit for predicting tumor immunotherapy curative effect and / or adverse reaction, and belongs to the technical field of biomedicine. The invention provides application of a reagent for detecting NKG7 in preparation of a kit for predicting tumor immunotherapy curative effect and / or adverse reaction. According to the application provided by the invention, by detecting the expression of the NKG7 and predicting the curative effect and adverse reaction of immunotherapy, dominant people suitable for immunotherapy can be further accurately screened, accurate treatment of tumors is realized, and prognosis of tumor patients is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to the use of a reagent for detecting NKG7 in preparing a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy. Background Art

[0002] At present, immune checkpoint inhibitors (ICIs) have been widely approved for the treatment of lung cancer, head and neck squamous cell carcinoma, bladder cancer, renal cancer, malignant melanoma and various solid tumors with DNA mismatch repair deficiency, significantly improving the survival of cancer patients. ICIs improve the anti-tumor effect of the immune system by blocking negative regulatory proteins of T cell activation such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 and its ligand (programmed death-1 / programmed death ligand-1, PD-1 / PD-L1).

[0003] However, not all patients can benefit from treatment, and the overall objective rate of patients receiving monotherapy with immune checkpoint inhibitors is still low. At the same time, the immune dysfunction caused by ICIs can affect multiple tissues and organs throughout the body, such as the skin, heart, gastrointestinal tract, and musculoskeletal system, leading to a series of unique immune-related adverse reactions (irAEs), resulting in treatment interruption or even life-threatening. Therefore, predictive biomarkers of efficacy and adverse reactions are needed to screen potential clinical benefit populations and achieve precision tumor treatment. Currently, only tumor characteristics such as PDL1 expression or DNA mismatch repair genes are used in clinical practice, but the predictive value is limited, and these predictive markers are derived from local tissues and cannot achieve dynamic monitoring during treatment. Therefore, it is necessary to explore and develop new and effective biomarkers for the efficacy and adverse reactions of immunotherapy. Summary of the invention

[0004] The purpose of the present invention is to provide an application of a reagent for detecting NKG7 in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy. The application provided by the present invention can predict the efficacy and adverse reactions of immunotherapy by detecting the expression of NKG7, further accurately screen the superior population suitable for immunotherapy, achieve accurate treatment of tumors, and improve the prognosis of tumor patients.

[0005] The present invention provides the use of a reagent for detecting NKG7 in preparing a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy.

[0006] The present invention also provides the use of a reagent for detecting NKG7 in tumor tissue, soluble NKG7 in plasma and / or NKG7 in plasma exosomes in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy.

[0007] The present invention also provides the use of a reagent for detecting soluble NKG7 in plasma in preparing a kit having the effects of any one or more of ① to ③:

[0008] ① Predict thyroid-related irAEs;

[0009] ②Prediction of immune hypopituitarism;

[0010] ③Predict grade II-III skin-related irAEs.

[0011] The present invention also provides the use of a reagent for detecting exosomal NKG7 in plasma in the preparation of a kit for predicting heart-related irAE and / or predicting grade III irAE.

[0012] The present invention also provides the use of a reagent for detecting the proportion of peripheral blood NKG7high CD8+T cells and / or detecting the expression of NKG7 in peripheral blood NKG7highCD8+T cells in the preparation of a kit for predicting tumor immune-related adverse reactions.

[0013] The present invention also provides the use of a reagent for detecting the proportion of peripheral blood NKG7high CD8+T cells and / or detecting the expression of NKG7 in peripheral blood NKG7highCD8+T cells in the preparation of a kit having any one or more of the effects described in a to c:

[0014] a. Prediction of immune myocarditis;

[0015] b. Prediction of immune arthritis;

[0016] c. Prediction of immune thyroiditis.

[0017] The present invention also provides the use of a reagent for overexpressing NKG7 in preparing a product for improving the killing function of NK cells.

[0018] The present invention also provides the use of an agent that overexpresses NKG7 in preparing a drug for enhancing the therapeutic effect of tumor immunotherapy.

[0019] Preferably, the tumor comprises a solid tumor.

[0020] The present invention provides the use of a reagent for detecting NKG7 in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy. The present invention first discovered that the expression of NKG7 in tumor tissue and plasma of tumor patients is related to the efficacy and adverse reactions of immunotherapy, and first proved that NKG7 can be used as a marker for predicting the efficacy of immunotherapy. At the same time, the present invention first determined that NKG7high CD8+T cells in peripheral blood are irAE-driving cell subpopulations, which can be used as an indicator for predicting irAE. The prediction of NKG7 expression level for immunotherapy is earlier than clinical imaging evaluation, and the detection is convenient and less invasive, and has good practical application value. In addition, the present invention also proves that by increasing the expression of NKG7 in immune cells, the killing effect of its exosomes on tumors can be increased, thereby improving the efficacy of immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 The present invention provides a graph of the analysis results of detecting the expression of NKG7 in the local tumor of a tumor patient by immunohistochemistry and the relationship between its expression and the efficacy of immunotherapy; wherein, A: a graph of the expression of NKG7 protein in the tumor tissue of patients with lung cancer, gastric cancer and esophageal cancer by immunohistochemistry, 100× represents the original magnification of 100 times, scale bar = 200μm, 400× represents the original magnification of 400 times, scale bar = 50μm; (B, C) immunohistochemical detection of patients who respond to immunotherapy (Responder) and those who are immune Result diagram of NKG7 protein expression in tissues of nonresponders, where B: Figure shows the results of immunohistochemistry detection, 200× represents the original magnification of 200 times, scale bar = 100μm, 400× represents the original magnification of 400 times, scale bar = 50μm, C: Figure shows the results of immunohistochemistry score calculation of 3 randomly selected fields of view for each pathological section; D: ROC curve of NKG7 expression level in tumor tissue predicting the efficacy of immunotherapy, ***P<0.001;

[0023] Figure 2The present invention provides a graph of the analysis result of detecting the level of soluble NKG7 in the plasma of tumor patients before and after treatment by ELISA and the relationship between the level and the efficacy of immunotherapy; wherein, A: a graph of the level of soluble NKG7 in the plasma of tumor patients before treatment (baseline) by ELISA; B: a graph of the level of soluble NKG7 in the plasma of tumor patients after treatment by ELISA, *P<0.05, ns represents no significant statistical difference;

[0024] Figure 3 The present invention provides a graph of the analysis results of soluble NKG7 levels in the plasma of tumor patients before and after treatment by ELISA, as well as the levels and irAEs; wherein, A: a graph of the results of ELISA detection of soluble NKG7 levels in the plasma of tumor patients with different irAE types before (baseline) and after treatment; B: a graph of the ratio of soluble NKG7 in the plasma of tumor patients with different irAE types after immunotherapy to NKG7 in the plasma before treatment (baseline); C: a trend line graph of changes in soluble NKG7 levels in the plasma of patients without irAEs and patients with grade II-III skin-related irAEs before (baseline) and after treatment, *P<0.05, ns represents no significant statistical difference;

[0025] Figure 4 The present invention provides a graph of the analysis results of the levels of exosomal NKG7 in the plasma of tumor patients before and after treatment by ELISA, and the levels and irAEs; wherein, A: a graph of the results of ELISA detection of the levels of exosomal NKG7 in the plasma of tumor patients with different irAE types before (baseline) and after treatment; B: a trend line graph of the changes in the levels of exosomal NKG7 in the plasma of patients without irAE and patients with heart-related irAE before (baseline) and after treatment, *P<0.05, ns represents no significant statistical difference; C: a graph of the results of ELISA detection of the levels of exosomal NKG7 in the plasma of tumor patients with different irAE grades before (baseline) and after treatment;

[0026] Figure 5 The present invention provides a result diagram based on Bukhari single cell data, which clearly shows that NKG7high CD803 Teff is the driving subpopulation of irAE; wherein, A: UMAP visualization result diagram of each cell subpopulation; B: expression diagram of each cell marker in different cell subpopulations; C: UMAP diagram of the proportion of CD803 Teff and the distribution of each cell subpopulation in irAE and non-irAE patients at baseline and after treatment; D: comparison diagram of the changes in the proportion of each cell subpopulation before and after treatment in irAE and non-irAE patients; E: result diagram of distinguishing various types of irAE (immune arthritis, immune pneumonia, immune neuritis) from patients without irAE according to the proportion of CD803 Teff and its NKG7 expression;

[0027] Figure 6 The present invention provides a result diagram based on Zhu single cell data to verify that NKG7high CD803 Teff is the driving subpopulation of irAE; wherein, A: UMAP visualization result diagram of each cell subpopulation; B: expression diagram of each cell marker in different cell subpopulations; C: UMAP diagram of the proportion of CD803 Teff and the distribution of each cell subpopulation after treatment of irAE and non-irAE patients; D: comparison result diagram of the proportion of each cell subpopulation after treatment of irAE and non-irAE patients; E: result diagram of distinguishing patients with immune myocarditis from patients without irAE according to the proportion of CD803 Teff and its NKG7 expression;

[0028] Figure 7 The characteristic gene result diagram for determining the NKG7high CD803 Teff cell subset provided by the present invention; wherein, A: volcano diagram of differential genes between CD803 Teff and CD802 Tem in Bukhari data; B: volcano diagram of differential genes between CD803 Teff and CD804 Teff in Bukhari data; C: volcano diagram of differential genes between CD803 Teff and CD802 Tm in Zhu data; D: volcano diagram of differential genes between CD803Teff and CD804 Teff in Zhu data; E: Venn diagram of differential genes highly expressed in CD803 Teff; F: receiver operating characteristic curve (ROC) result diagram of each characteristic gene in Bukhari data for identifying CD803 Teff from CD8 cells; F: receiver operating characteristic curve (ROC) result diagram of each characteristic gene in Zhu data for identifying CD803 Teff from CD8 cells;

[0029] Figure 8 The result diagram of the increase in the ratio of NKG7high CD803 Teff provided by the present invention can predict immune hypothyroidism; wherein, A: UMAP visualization result diagram of each cell subset; B: expression diagram of each cell marker in different cell subsets; C: trend diagram of CD803 Teff ratio changes in 4 patients at baseline and after 2 cycles of treatment; D: UMAP diagram of the ratio of CD803 Teff and the distribution of each cell subset in irAE and non-irAE patients at baseline and after 2 cycles of treatment; E: trend diagram of the ratio of CD803Teff and thyroid stimulating hormone levels in 4 patients at baseline, 2 cycles of treatment and subsequent cycles;

[0030] Fig. 9The results of the knockdown of NKG7 provided by the present invention inhibiting the killing effect of extracellular vesicles secreted by equal amounts of cells on tumor cells; wherein, A: a schematic diagram of an experiment in which equal amounts of NK cell extracellular vesicles secreted by cells were collected (control group and stable knockdown NKG7 group), and the changes in the characteristics of the extracellular vesicles were analyzed and the changes in the killing effect were detected by co-culturing with tumor cells 721.221; B: the MTS method was used to detect the death ratio of tumor cells after co-culture with YTS extracellular vesicles; C: the MTS method was used to detect the death ratio of tumor cells after co-culture with NK92MI extracellular vesicles; D: flow cytometry Detection of apoptosis of tumor cells after co-culture with YTS extracellular vesicles; (left) is the result of flow cytometry; (right) is the statistical result; E: Detection of apoptosis of tumor cells after co-culture with NK92MI extracellular vesicles by flow cytometry; (left) is the result of flow cytometry; (right) is the statistical result; AnnV-PI-, living cells; AnnV+PI-, early apoptotic cells; AnnV+PI+, late apoptotic cells; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001;

[0031] Fig.10 The results of the knockdown of NKG7 provided by the present invention inhibiting the killing effect of equal amounts of extracellular vesicles on tumor cells; wherein, A: a schematic diagram of an experiment for collecting equal amounts of extracellular vesicles (control group and stable knockdown NKG7 group), analyzing changes in extracellular vesicle characteristics and detecting changes in killing effects by co-culturing with tumor cells; B: MTS method for detecting the death ratio of tumor cells after co-culture with NK cell extracellular vesicles; (left) YTS extracellular vesicles; (right) NK92MI extracellular vesicles; C: flow cytometry for detecting apoptosis of tumor cells after co-culture with NK cell extracellular vesicles; AnnV-PI-, living cells; AnnV+PI-, early apoptotic cells; AnnV+PI+, late apoptotic cells; D: statistical results of apoptosis of tumor cells after co-culture with NK cell extracellular vesicles; (left) YTS extracellular vesicles; (right) NK92MI extracellular vesicles; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001;

[0032] Fig.11The present invention provides a result diagram of overexpression of NKG7 promoting the secretion of extracellular vesicles by equal amounts of cells and promoting the killing effect of equal amounts of extracellular vesicles on tumor cells; wherein, A: MTS method detects the death ratio of tumor cells after co-culture with equal amounts of extracellular vesicles secreted by NK cells; B: flow cytometry detects the apoptosis of tumor cells after co-culture with equal amounts of extracellular vesicles secreted by NK cells; AnnV-PI-, living cells; AnnV+PI-, early apoptotic cells; AnnV+PI+, late apoptotic cells; C: statistical results of apoptosis of tumor cells after co-culture with equal amounts of extracellular vesicles secreted by NK cells; D: MTS method detects the death ratio of tumor cells after co-culture with equal amounts of extracellular vesicles of NK cells; E: flow cytometry detects the apoptosis of tumor cells after co-culture with equal amounts of extracellular vesicles of NK cells; F: statistical results of apoptosis of tumor cells after co-culture with equal amounts of extracellular vesicles of NK cells; **P<0.01, ***P<0.001, ****P<0.0001;

[0033] Fig.12 The in vivo experiment provided by the present invention verifies that NKG7 promotes the killing effect of NK cell extracellular vesicles on tumors; wherein, A: animal experiment flow chart (721.221 tumor cell line was subcutaneously injected into NOG mice, and NK cell extracellular vesicles or PBS were injected into the tumor twice a week after tumor formation); B and C are display diagrams of subcutaneous tumor nodules in mice at the end of the experiment; D: mouse tumor weight statistics, N=6; E: mouse tumor volume growth curve, N=6; F: mouse body weight growth curve, N=6; G: mouse tumor tissue HE staining, CD31 and Ki67 immunohistochemical staining results; H: 3 fields of view randomly selected from each pathological section to calculate the immunohistochemical score result diagram, N=6, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns represents no significant statistical difference. DETAILED DESCRIPTION

[0034] The present invention provides the use of a reagent for detecting NKG7 in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy. Natural killer cell granule protein-7 (NKG7) was first described as an intrinsic membrane protein associated with the cytotoxic granules of natural killer (NK) cells. In the present invention, the NKG7 is preferably human NKG7. The human NKG7 detected by the present invention is preferably proteinNKG7isoform 1 [Homo sapiens], NCBI sequence number: NP_005592.1, UniProt number: Q16617. The present invention found that NKG7 can be used as a biomarker for the efficacy and adverse reactions of tumor (including solid tumor) immunotherapy. In the present invention, the tumor preferably includes a solid tumor. In one embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, liver cancer, tongue cancer and pancreatic cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, esophageal cancer, colorectal cancer, liver cancer, bile duct cancer, cervical cancer, breast cancer, skin cancer, kidney cancer, bladder cancer, nasopharyngeal cancer, hypopharyngeal cancer and tongue cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, colon cancer, esophageal cancer, breast cancer, skin cancer and bladder cancer.

[0035] The present invention also provides the use of a reagent for detecting NKG7 in tumor tissue, soluble NKG7 in plasma, and / or NKG7 in plasma exosomes in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy. The present invention also provides the use of a reagent for detecting soluble NKG7 in plasma in the preparation of a kit having any one or more of the functions as described in ① to ③: ① predicting thyroid-related irAEs; ② predicting immune hypopituitarism; ③ predicting grade II-III skin-related irAEs. The experimental results showed that NKG7 was expressed in immune cells infiltrating tumor tissue (taking lung cancer, gastric cancer and esophageal cancer as examples), and was highly correlated with the efficacy of immunotherapy in patients. Immunotherapy was effective in patients with high NKG7 expression, and local NKG7 expression in tumors could be used as a prognostic marker for patients receiving immunotherapy. The level of soluble NKG7 in plasma was highly correlated with the efficacy and adverse reactions of immunotherapy in patients. The high level of soluble NKG7 in the patient's plasma before treatment indicated that immunotherapy was effective. The low level of soluble NKG7 in the patient's plasma before and after treatment indicated that the patient was more likely to develop thyroid-related irAEs. The high level of soluble NKG7 in the patient's plasma after treatment indicated that the patient was more likely to develop hypopituitarism. The significant increase in soluble NKG7 in the patient's plasma during treatment indicated that the patient was more likely to develop grade II-III skin-related irAEs. The level of plasma soluble NKG7 could be used as a predictive marker for the efficacy and adverse reactions of immunotherapy in patients.

[0036] The present invention also provides the use of a reagent for detecting exosome NKG7 in plasma in the preparation of a kit for predicting cardiac-related irAE and / or predicting grade III irAE. Plasma exosome NKG7 expression is highly correlated with the occurrence of adverse reactions related to immunotherapy in patients. Patients with high levels of exosome NKG7 in plasma are more likely to have cardiac-related adverse reactions to immunotherapy and grade III adverse reactions to immunotherapy. Plasma exosome NKG7 expression can be used as a prognostic marker for adverse reactions in immunotherapy patients. In the present invention, the tumor preferably includes a solid tumor. In one embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, liver cancer, tongue cancer and pancreatic cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, esophageal cancer, colorectal cancer, liver cancer, bile duct cancer, cervical cancer, breast cancer, skin cancer, kidney cancer, bladder cancer, nasopharyngeal cancer, hypopharyngeal cancer and tongue cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, colon cancer, esophageal cancer, breast cancer, skin cancer and bladder cancer. 。

[0037] The present invention also provides the use of a reagent for detecting the proportion of NKG7high CD8+T cells in peripheral blood and / or detecting the expression of NKG7 in NKG7highCD8+T cells in peripheral blood in the preparation of a kit for predicting tumor immune-related adverse reactions. The present invention also provides the use of a reagent for detecting the proportion of NKG7high CD8+T cells in peripheral blood and / or detecting the expression of NKG7 in NKG7high CD8+T cells in peripheral blood in the preparation of a kit having any one or more of the functions described in a to c: a. Predicting immune myocarditis; b. Predicting immune arthritis; c. Predicting immune thyroiditis. The present invention found that NKG7high CD8+T cells are irAE-driven subpopulations, and clarified their characteristic genes, and the characteristic gene is NKG7. The proportion of NKG7high CD8+T cells and their NKG7 expression can distinguish irAE and non-irAE patients, especially immune myocarditis and immune arthritis. The present invention found that by monitoring the dynamic changes in the proportion of NKG7high CD8+T cells in peripheral blood at the baseline of treatment and after 2 cycles of treatment, the occurrence of thyroid-related irAEs can be predicted early.

[0038] The present invention also provides the use of an agent that overexpresses NKG7 in the preparation of a product that improves the killing function of NK cells. The present invention also provides the use of an agent that overexpresses NKG7 in the preparation of a drug that enhances the efficacy of tumor immunotherapy. In the present invention, the tumor preferably includes a solid tumor. In one embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, esophageal cancer, gastric cancer, intestinal cancer, breast cancer, liver cancer, tongue cancer and pancreatic cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, esophageal cancer, colorectal cancer, liver cancer, bile duct cancer, cervical cancer, breast cancer, skin cancer, kidney cancer, bladder cancer, nasopharyngeal cancer, hypopharyngeal cancer and tongue cancer. In another embodiment of the present invention, the solid tumor preferably includes any one or more of lung cancer, gastric cancer, colon cancer, esophageal cancer, breast cancer, skin cancer and bladder cancer.

[0039] To further illustrate the present invention, the application of the reagent for detecting NKG7 provided by the present invention in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0040] Example 1

[0041] NKG7 is expressed in tumor-infiltrating immune cells and can predict the efficacy of immunotherapy in tumor patients. Immunotherapy is effective in patients with high NKG7 expression (H-scored>5).

[0042] 1 Experimental methods

[0043] (1) Research subjects and tissue sample collection

[0044] The present invention included 30 tumor patients who received immunosuppressive therapy in the First Affiliated Hospital of China Medical University from May 2018 to April 2023, including 14 lung cancer patients, 10 gastric cancer patients and 6 esophageal cancer patients. The basic information, clinical course, treatment information and results of the patients were collected from the medical records. The efficacy outcomes were evaluated by clinicians according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Patients with the best treatment response of complete response (CR) and partial response (PR) were defined as responders to immunotherapy, and patients with the best treatment response of progressive disease (PD) and stable disease (SD) were defined as nonresponders to immunotherapy. The patients provided written informed consent before surgery and obtained approval from the hospital ethics committee (ethics approval number: Kelun Shen 2022

[216] ). The clinical data of the patients are summarized in Table 1.

[0045] Table 1 Clinical data of patients

[0046] feature Number of cases (%) gender male 25(83.3) female 5(16.7) Tumor type Lung cancer 14(46.7) Gastric cancer 10(33.3) Esophageal cancer 6(20.0) Number of previous treatment lines 0 18(60.0) 1 10(33.3) 2 2(6.7)

[0047] Note: Median age (years / range): 64 years (44-75 years).

[0048] (2) Immunohistochemical staining

[0049] Each tumor tissue specimen was fixed with 10% formalin, embedded in paraffin and sliced ​​continuously. After the paraffin sections were heated in an oven at 70°C for 4 hours, they were dewaxed in a gradient manner using xylene I, xylene II, anhydrous ethanol, 95% ethanol, and 75% ethanol, and finally soaked in distilled water. The sections were then placed in 0.01M citrate buffer, treated with high pressure for 8 minutes, and cooled naturally at room temperature. After rinsing with PBS, solution A (hydrogen peroxide) was added for 10 minutes; after rinsing with PBS, solution B (super blocking solution) was added and blocked for 1 hour. 200μl of primary antibody (NKG7 antibody #84835S, Cell Signaling Technology, USA) diluted with PBS was added to the sections and incubated overnight at 4°C. The next day, after rinsing with PBS, solution C (primary antibody amplification solution) was added for 10 minutes. After rinsing with PBS, solution D (enzyme-labeled secondary antibody polymer) was used for 20 minutes. After rinsing with PBS, the DAB staining solution was quickly added to the slices. After the slices were observed under the microscope and fully colored, the reaction was terminated by soaking the slices in distilled water. The slices were counterstained with hematoxylin for 1 minute and rinsed with running water for 10 minutes. The slices were dehydrated in 75% ethanol, 95% ethanol, anhydrous ethanol I, and anhydrous ethanol II for 5 minutes each and then removed. The slices were first placed in xylene I for 10 minutes, then in xylene II for 10 minutes, and finally sealed with neutral gum. The entire tissue specimen was scanned under a low-power microscope (10x) to evaluate the staining, and three fields of view were randomly selected under a high-power microscope (20x) to take pictures and record. The protein expression was scored according to the percentage of positive cells and the staining intensity. The staining intensity score was: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The frequency of positive cells was defined as: ≤5% for 0 points; 5-25% for 1 point; 26-50% for 2 points; 51-75% for 3 points; >75% for 4 points. Histological score (H-score) = staining intensity score × positive cell frequency score. The scoring was performed by two independent pathologists, and the ROC curve was drawn using GraphPadPrism software.

[0050] (3) Statistical analysis

[0051] Statistical analysis was performed using GraphPadPrism software (Version 8.0.2). All mean values ​​were calculated from at least 3 independent experiments, and the data were expressed as mean ± standard deviation. Differences were analyzed using Student's t test. P values ​​less than 0.05 were considered statistically significant.

[0052] 2 Experimental results

[0053] The present invention collected tumor tissue specimens from 30 tumor patients who were treated with immunotherapy and performed immunohistochemical staining analysis. The immunohistochemical results showed that NKG7 was mainly expressed in tumor-infiltrating immune cells (see Figure 1A in the figure), and its expression level was significantly correlated with the efficacy of immunotherapy (P<0.05) (see Figure 1 B and Figure 1 C), patients with high NKG7 expression are effective in immunotherapy. The ROC curve results show that local NKG7 expression in tumors is a good marker for predicting the efficacy of immunotherapy. When H-score = 5 is used to define high and low expression of NKG7, its sensitivity for predicting effective immunotherapy is 73.3% and its specificity is 86.7%; when H-score = 2.5 is used to define high and low expression of NKG7, its sensitivity for predicting effective immunotherapy is 100% and its specificity is 60% (see Figure 1 D).

[0054] 3 Experimental conclusions

[0055] The present invention found that NKG7 is expressed in immune cells infiltrating tumor tissues of patients with lung cancer, gastric cancer and esophageal cancer, and is highly correlated with the efficacy of immunotherapy in patients. Immunotherapy is effective in patients with high NKG7 expression (H-scored>5). NKG7 expression in local tumor tissues can be used as a prognostic marker for patients undergoing immunotherapy.

[0056] Example 2

[0057] The level of soluble NKG7 in the plasma of tumor patients before immunotherapy can predict the efficacy of immunotherapy.

[0058] 1 Experimental methods

[0059] (1) Patients and tissue samples

[0060] The patient plasma included in the present invention was obtained from the First Affiliated Hospital of China Medical University. The patient provided written informed consent before the sample was collected, and the Ethics Committee of the First Affiliated Hospital of China Medical University was approved (Ethics Approval Number: Kelun Shen 2022

[216] ). The present invention included 87 tumor patients who received single-agent immunosuppressant treatment at the First Affiliated Hospital of China Medical University from January 2018 to December 2020, including 46 lung cancer patients, 6 gastric cancer patients, 6 esophageal cancer patients, 8 intestinal cancer patients, 5 gynecological tumor patients, and 16 other tumor patients (breast cancer, liver cancer, tongue cancer, pancreatic cancer, etc.). The basic information, clinical course, treatment information and results of the patients were collected from the medical records. The efficacy outcomes were evaluated by clinicians according to RECIST version 1.1. Patients with the best treatment response of CR and PR were defined as responders to immunotherapy, and patients with the best treatment response of PD and SD were defined as non-responders to immunotherapy. The clinical data of the patients are summarized in Table 2.

[0061] Table 2 Clinical data of patients

[0062] feature Number of cases (%) gender male 54(62.1) female 33(37.9) Tumor type Lung cancer 46(52.9) Gastric cancer 6(6.9) Esophageal cancer 6(6.9) Bowel cancer 8(9.2) Gynecological tumors 5(5.7) Other tumors 16(18.4) Number of previous treatment lines 0 17(19.5) 1 44(50.6) 2 17(19.5) ≥3 9(10.3) ICI Type PD1 inhibitors 81(93.1) PDL1 inhibitors 6(6.9)

[0063] Note: Median age (years / range): 60 years (30-76 years).

[0064] Plasma samples were collected from patients before and after treatment (at the time of the first efficacy evaluation after 2 cycles of medication), and whole blood was collected in venous blood collection tubes containing EDTA. The blood samples in the blood collection tubes were centrifuged at 3,000 rpm at 4°C for 10 minutes within 1 hour, and then the upper plasma phase was carefully transferred to a new tube and stored in a -80°C refrigerator.

[0065] (2)ELISA

[0066] The expression of soluble NKG7 in patient plasma was detected by enzyme-linked immunosorbent assay (ELISA) using the Human NKG7 ELISA Detection Kit (Assay Genie #HUEB1938). Add 100 μl of plasma or the standard in the kit to each well and keep at room temperature for 2 hours. After the liquid is completely discarded, add 100 μL of detection reagent A to each well and incubate at 37°C for 1 hour. Wash each well 3 times with wash buffer, then add 100 μl of detection reagent B and incubate at 37°C for 1 hour. Then, wash each well 5 times with wash buffer. Add 90 μl of substrate to each well and incubate at 37°C for 20 minutes. Add 50 μl of stop solution to each well and immediately measure the results by measuring the absorbance at 450 nm using the Bio-RADi Mark.

[0067] (3) Statistical analysis

[0068] See Example 1

[0069] 2 Experimental results

[0070] Clinically, it is difficult to obtain pathological samples from tumor patients, and invasive procedures bring additional pain to patients. In order to develop a clinically feasible detection method, the present invention collected plasma samples from 87 tumor patients who were treated with immunotherapy, and analyzed the correlation between the expression level of soluble NKG7 in the patient's plasma and the efficacy of immunotherapy by ELISA. Figure 2 A and Figure 2 The results in B showed that patients with a complete or partial response to immunotherapy had higher soluble NKG7 expression in plasma before treatment compared with patients who did not respond to immunotherapy, while patients who did not respond to immunotherapy had lower soluble NKG7 expression in plasma before treatment.

[0071] 3 Experimental conclusions

[0072] The present invention found that the level of plasma soluble NKG7 is highly correlated with the efficacy of immunotherapy in patients. The high level of soluble NKG7 in the patient's plasma before treatment indicates that immunotherapy is effective. The level of plasma soluble NKG7 can be used as a predictive marker for the efficacy of immunotherapy in patients.

[0073] Example 3

[0074] The level of soluble NKG7 in plasma can predict the occurrence of different types of adverse immune reactions in patients receiving immunotherapy.

[0075] 1 Experimental methods

[0076] (1) Patients and tissue samples

[0077] The present invention includes 142 patients who received immunotherapy before and after treatment, including lung cancer, gastric cancer, esophageal cancer and others (colorectal cancer, liver cancer, bile duct cancer, cervical cancer, breast cancer, skin cancer, kidney cancer, bladder cancer, nasopharyngeal cancer, hypopharyngeal cancer, tongue cancer) plasma specimens to detect the level of soluble NKG7. Plasma was obtained from the First Affiliated Hospital of China Medical University. The patient provided written informed consent before the sample was retained, and the Ethics Committee of the First Affiliated Hospital of China Medical University was approved. Patients diagnosed with malignant tumors and receiving immunotherapy. Patients had histologically confirmed cancer. Further eligibility criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate hematological and biochemical values, and no known hypersensitivity to PD-1 monoclonal antibodies. Patients who had previously received drugs targeting immune checkpoint pathways (including drugs targeting PD-1, PD-L1 or PD-L2 or CTLA-4) were excluded. All patients at the First Affiliated Hospital of China Medical University received immunotherapy according to standard protocols. The clinical information of all patients was retrieved from the hospital information system. The degree of irAE in patients was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAEs). The data on the type and grade of adverse immune reactions in patients are summarized in Table 3.

[0078] Table 3 Data on the types and grades of adverse immune reactions in patients

[0079] Classification Number of cases Types of irAEs Thyroid-related irAEs 33 Skin-related irAEs 12 Cardiac irAEs 5 Liver impairment 9 Lung-related irAEs 8 Hypopituitarism 5 enteritis 4 other 3 No irAEs 63 irAE grade G1 29 G2 28 G3 22 No irAEs 63

[0080] (2)ELISA

[0081] See Example 2.

[0082] (3) Statistical analysis

[0083] Statistical analysis was performed using R software (R-4.1.0). Differences were analyzed using the Wilcoxon rank sum test. P values ​​less than 0.05 were considered statistically significant.

[0084] 2 Experimental results

[0085] The side effects of immune checkpoint inhibitors are different from other anti-tumor drugs and may occur in any organ or tissue in the body, such as the skin, digestive organs, respiratory organs, thyroid gland and pituitary gland. In particular, irAEs above level III will affect organ function, reduce the quality of life of patients, lead to discontinuation of treatment, and may even be fatal. The present invention collected plasma specimens from 142 tumor patients who received immunotherapy before and after treatment, and analyzed the correlation between the level of soluble NKG7 in the patient's plasma and immunotherapy-related adverse reactions by ELISA. Figure 3 The results of A in Figure 2 showed that the levels of soluble NKG7 in the plasma of patients with thyroid-related irAEs at baseline and after treatment were significantly lower than those in patients without irAEs, and the levels of soluble NKG7 in the plasma of patients with hypopituitarism after treatment were significantly higher than those in patients without irAEs (see Figure 3 In addition, the present invention found that after receiving immunotherapy, the level of soluble NKG7 in the plasma of patients with grade II-III skin-related irAEs was significantly increased compared with the baseline (see Figure 3 B and Figure 3 C). The results suggest that elevated plasma soluble NKG7 levels are a good predictive marker for grade II-III skin-related irAEs.

[0086] 3 Experimental conclusions

[0087] The present invention found that the level of plasma soluble NKG7 is highly correlated with adverse reactions in patients. Low levels of soluble NKG7 in patient plasma before and after treatment indicate that patients are more likely to have thyroid-related irAEs, and high levels of soluble NKG7 in patient plasma after treatment indicate that hypopituitarism is more likely to occur. In addition, a significant increase in soluble NKG7 levels during treatment indicates that patients are more likely to have grade II-III skin-related irAEs. Therefore, the level of plasma soluble NKG7 can be used as a predictive marker for different types of adverse immune reactions.

[0088] Example 4

[0089] The level of exosomal NKG7 in plasma can predict the occurrence of cardiac-related and grade III adverse reactions of immunotherapy in patients receiving immunotherapy.

[0090] 1 Experimental methods

[0091] (1) Patients and tissue samples

[0092] The present invention includes plasma samples from 27 patients with lung cancer, gastric cancer, colon cancer, esophageal cancer, breast cancer, skin cancer, and bladder cancer who were treated with immunotherapy before and after treatment to detect the level of exosomal NKG7. The collection of plasma samples is shown in Example 3. The data on the types and grades of adverse immune reactions of patients are summarized in Table 4.

[0093] Table 4 Data on the types and grades of adverse immune reactions in patients

[0094] Classification Number of cases Types of irAEs Thyroid-related irAEs 10 Skin-related irAEs 5 Cardiac irAEs 3 Liver impairment 2 Lung-related irAEs 1 Hypopituitarism 1 No irAEs 5 irAE grade G1 10 G2 5 G3 7 No irAEs 5

[0095] (2) Isolation and purification of plasma exosomes

[0096] Take out the frozen plasma and slowly thaw it at 4℃. Centrifuge it at 5000rpm at 4℃ for 15 minutes to remove cell debris, and transfer the supernatant to a new EP tube. To remove fibrinogen, add 3.2μL thrombin (611U / mL, EXOQ5TM-1, SBI) to every 0.4mL plasma. After incubation at room temperature for 10 minutes, centrifuge it at 10000rpm at 4℃ for 10 minutes. Fibrin particles can be seen at the bottom of the tube. Transfer the serum sample supernatant to a new centrifuge tube, and add 100μl ExoQuick to every 400μl supernatant. TM Exosome Precipitation Solution (EXOQ5TM-1, SBI). Mix well and incubate at 4°C for 30 minutes. Centrifuge at 1500g for 30 minutes at room temperature, discard the supernatant, and add lysis buffer to the precipitate to resuspend.

[0097] (3)ELISA

[0098] See Example 2.

[0099] (4) Statistical analysis

[0100] See Example 3.

[0101] 2 Experimental results

[0102] The present invention collected plasma samples from 27 tumor patients before and after immunotherapy, and analyzed the correlation between the level of exosomal NKG7 in the patient's plasma and irAE by ELISA. The results showed that the expression of exosomal NKG7 was detected in the plasma of the three patients with cardiac-related irAE after treatment, and its level was significantly higher than the baseline (see the results). Figure 4 A and Figure 4 The expression of exosomal NKG7 in the plasma of patients with other types of irAE and those without irAE was extremely low (see the results in Figure 4The results show that the level of exosomal NKG7 in plasma is a good predictive marker for adverse reactions to cardiac-related immunotherapy. In addition, more abundant exosomal NKG7 can be detected in the plasma of patients with grade III irAE after treatment, while the overall expression of exosomal NKG7 in the plasma of patients without irAE and patients with grade I-II irAE is extremely low (see the results). Figure 4 C). The results indicate that the level of exosomal NKG7 in plasma is a predictive marker for grade III adverse reactions to immunotherapy.

[0103] 3 Experimental conclusions

[0104] The present invention found that the level of plasma exosomal NKG7 is highly correlated with the occurrence of cardiac-related immunotherapy adverse reactions and grade III immunotherapy adverse reactions in patients. Patients in whom exosomal NKG7 is detected in plasma after immunotherapy are more likely to have cardiac-related immunotherapy adverse reactions and grade III immunotherapy adverse reactions. The level of plasma exosomal NKG7 can be used as a prognostic marker for cardiac-related and grade III immunotherapy adverse reactions in patients receiving immunotherapy.

[0105] Example 5

[0106] NKG7high CD8+T cells are irAE-driving subsets

[0107] 1 Experimental methods

[0108] (1) Data collection: The present invention collects Bukhari (GSE216329) and Zhu (GSE180045) single-cell transcriptome sequencing data. The Bukhari dataset contains single-cell data of peripheral T cells from 15 patients receiving immunotherapy at baseline and after treatment. Among them, 6 patients developed irAEs, while 9 patients did not develop irAEs. The Zhu dataset contains peripheral blood single-cell data from 13 patients after immunotherapy. Among them, 10 patients developed irAEs, while 3 patients did not develop irAEs.

[0109] (2) Data analysis: The present invention performs quality control based on the number of genes and mitochondrial ratio to filter out cells that do not meet the requirements, uses the Seurat R package and the PCA algorithm to perform cell dimensionality reduction clustering on the two single-cell data, and then visualizes the results using the UMAP (Uniform Manifold Approximation and Projection) algorithm.

[0110] (3) T cell subset annotation: Based on the recognized cell markers of T cell subsets (original state: TCF7, CCR7, LEF1, SELL; memory state: IL7R, ANXA1, GZMK, CXCR3; effector state: NKG7, GZMH, CCL5, CST7; proliferation state: MKI67), the present invention annotates T cells into 9 different subsets, named CD401 Tn, CD402 Tm, CD403, CD404 Treg, CD801Tn, CD802 Tem, CD803 Teff, CD804 Teff and Tprolif. Since the Zhu dataset contains other immune cells besides T cells, the present invention first annotates the T cell population based on the expression of T cell marker genes CD3D and CD3E, and then annotates T cell subsets according to the above method.

[0111] 2 Experimental results:

[0112] In the Bukhari dataset, the present invention annotated a CD803 Teff cell subset characterized by high expression of NKG7 and other cytotoxic genes (see Figure 5 A and Figure 5 The UMAP scatter plot showed that the overall proportion of NKG7highCD803 Teff cells in irAE patients increased after treatment compared with baseline (10.3% vs 12.9%), while the proportion of NKG7highCD803 Teff cells in patients without irAEs decreased slightly after treatment compared with baseline (12.4% vs 12%) (see Figure 5 The present invention further calculated the difference between the changes in the proportion of each cell subset after treatment and at baseline for each patient, and the results showed that the changes in the proportion of NKG7high CD803 Teff cells in irAE patients were significantly higher than those in patients without irAE (see Figure 5 In addition, the present invention found that the proportion of NKG7high CD803 Teff cell subsets and the expression of NKG7 in patients with immune arthritis were significantly higher than those in patients without irAE. However, this difference was not significant in immune pneumonia and immune neuritis (see Figure 5 E).

[0113] In the Zhu dataset, the present invention also annotated NKG7high CD803 Teff cells. Similar to the Bukhari dataset, this group of cells highly expressed NKG7 and other cytotoxic genes (see Figure 6 A and Figure 6B in the figure). The UMAP scatter plot shows that the overall proportion of NKG7high CD803 Teff cells in irAE patients after treatment is higher than that in patients without irAE (9.2% vs 12.7%). The present invention further calculated the proportion of each cell subset after treatment for each patient, and the results showed that the proportion of NKG7high CD803 Teff cells in irAE patients after treatment was higher than that in patients without irAE (see Figure 6 C and Figure 6 D in). In addition, the present invention found that compared with patients without irAE, the proportion of NKG7high CD803 Teff cell subsets and the expression of NKG7 in patients with immune myocarditis were significantly higher.

[0114] 3 Experimental conclusions

[0115] The present invention found that the NKG7high CD8+T cell subpopulation is an irAE driving subpopulation. The increased proportion of NKG7high CD8+T cells and the high expression of NKG7 can indicate the occurrence of irAE, especially immune myocarditis and immune arthritis.

[0116] Example 6

[0117] Identification of signature genes of the CD803 Teff subset

[0118] 1 Experimental methods

[0119] (1) Gene differential expression analysis: The present invention uses wilcox.test to perform gene differential expression analysis. In the two data sets of Bukhari et al. and Zhu et al., CD803 Teff was compared with other CD8 T cells (CD803 Teff vs CD802 Tm, CD803 Teff vs CD804 Teff), and a volcano plot was drawn. The threshold was set to logFC value>0.5 and adj.P value<0.05. By taking the intersection of the differentially expressed genes in CD803 Teff cells, the present invention further determined the characteristic genes of CD803 Teff.

[0120] (2) Receiver operating characteristic (ROC) curve analysis: Based on the two data sets in Example 4, the present invention uses the "pROC" R package to draw the ROC curve of each characteristic gene to identify the CD803 Teff subpopulation from CD8 T cells, and calculates its corresponding area under the curve (AUC).

[0121] 2 Experimental results

[0122] Such as volcano map ( Figure 7 A in Figure 7As shown in D), the present invention obtains genes with high expression of CD803 Teff subgroup relative to CD802 and CD804 from Bukhari and Zhu datasets respectively. By further screening the intersection of these genes, the present invention finally determines the characteristic genes of 6 CD803 Teff subgroups including NKG7 (see Figure 7 E).

[0123] Based on the ROC curve (see Figure 7 F and Figure 7 G), the present invention determined that the AUC values ​​of NKG7 in the Bukhari and Zhu data sets were both at the forefront, which were 0.971 and 0.821, respectively.

[0124] 3 Experimental conclusions

[0125] The present invention found that high expression of NKG7 is the most significant feature of the NKG7high CD8+T cell subset (i.e., the CD803 Teff cell subset shown in the figure), which provides a key marker for the identification of this cell subset.

[0126] Example 7

[0127] NKG7high CD8+T cells can predict thyroid-related irAEs caused by immunotherapy

[0128] 1 Experimental methods

[0129] (1) Clinical sample collection: The present invention collected peripheral blood samples from 4 patients receiving immunotherapy at baseline and after 2 cycles of treatment for single-cell sequencing. Two of these patients developed immune hypothyroidism during subsequent treatment, and the other two patients did not develop any irAEs. The patients provided written informed consent before the samples were collected, and the Ethics Committee of the First Affiliated Hospital of China Medical University was approved.

[0130] (2) Data analysis: Same as Example 4.

[0131] (3) Cell annotation: same as Example 4.

[0132] 2 Experimental results:

[0133] The present invention annotates the NKG7high CD803 Teff cell subpopulation, which is characterized by high expression of NKG7 and other cytotoxic genes (see Figure 8 A and Figure 8 The trend chart shows that unlike patients without irAE (P1, P2), the proportion of NKG7high CD803 Teff cells in two patients with immune hypothyroidism (P3, P4) after 2 cycles of treatment was significantly higher than that at baseline (see Figure 8C in the figure). The UMAP scatter plot showed that the overall proportion of NKG7high CD803 Teff cells in patients with irAEs after 2 cycles of treatment increased compared with the baseline (35% vs 42.3%), while the overall proportion of NKG7high CD803 Teff cells in patients without irAEs after 2 cycles of treatment decreased compared with the baseline (47.1% vs 41.8%) (see Figure 8 In addition, the present invention found that the change in the ratio of NKG7highCD803Teff was consistent with the change trend of thyroid stimulating hormone (TSH) in peripheral blood (see Figure 8 E).

[0134] 3 Experimental conclusions

[0135] The present invention found that the proportion of NKG7high CD8+T cells in patients with immune hypothyroidism increased compared with the baseline after 2 cycles of immunotherapy. Therefore, by monitoring the increase in the proportion of NKG7high CD8+T cells, the occurrence of thyroid-related irAEs can be indicated early.

[0136] Example 8

[0137] In vitro experiments verified that NKG7 promotes the killing effect of NK cells on tumors

[0138] 1 Experimental methods

[0139] (1) Establishment of NK cell lines with stable knockdown and overexpression of NKG7

[0140] NKG7 short hairpin RNA (shRNA) and negative control lentivirus were purchased from Heyuan Biotechnology Co., Ltd. (Shanghai, China), and the sequences are as follows:

[0141] shNKG7-1: 5'-GCACCGATTTCTGGTTTGA-3' (SEQ ID NO. 1);

[0142] shNKG7-2: 5'-GGGTCTCAGCTATCCTCTT-3' (SEQ ID NO. 2);

[0143] NKG7 overexpression (OE) and negative control lentivirus were purchased from Heyuan Biotechnology Co., Ltd. (Shanghai, China). NK cell line YTS or NK92MI cells were cultured at 1×10 5The cells were inoculated at a density of 100 / well in a low-adhesion 6-well plate, and 8 μg / mL polybrene was added to improve the transfection efficiency. After adding the lentivirus and mixing well (MOI = 10 for YTS cells and MOI = 100 for NK92MI cells), the plate was sealed with a sealing film. The cells were centrifuged at 360g for 2 hours at 32°C, and continued to be cultured in an incubator after the centrifugation. 2 mL of complete culture medium was added after 4 hours. 48 hours after transfection, when the cells were in good condition, puromycin or blasticidin was used to screen the stably transfected cells according to the resistance label contained in the lentiviral vector, and the transfection efficiency was verified by Western Blot and subsequent experiments were carried out.

[0144] (2) Extracellular vesicle extraction

[0145] The inactivated fetal bovine serum and horse serum were centrifuged at 100,000g for 18 hours at 4°C to prepare fetal bovine serum and horse serum that had been depleted of extracellular vesicles. After the cells were washed with PBS, the cells were continued to be cultured in the culture medium prepared with fetal bovine serum and horse serum that had been depleted of extracellular vesicles, and the cell supernatant was collected after 48 hours. The cell supernatant was then centrifuged at 300g for 10 minutes at 4°C to remove dead cells, and the cell supernatant was collected; the cell supernatant was centrifuged at 2000g for 10 minutes at 4°C to remove cell debris, and the cell supernatant was collected; the cell supernatant was filtered through a filter with a pore size of 0.22μm, and the filtrate was collected using an ultracentrifuge tube; the filtrate was centrifuged at 100,000g for 2 hours at 4°C to enrich extracellular vesicles, and the supernatant was discarded; the precipitate was dissolved with PBS, and the extracellular vesicles were washed and removed from impurities by centrifugation at 100,000g for 2 hours at 4°C again; the PBS was discarded, and the white precipitate at the bottom of the ultracentrifuge tube was the extracellular vesicle. Resuspend the extracellular vesicles in an appropriate volume of PBS or lysis buffer for subsequent electron microscopy observation, particle size analysis, protein quantification, Western Blot, co-culture with tumor cells, in vivo animal experiments or store in a -80°C refrigerator.

[0146] (3) Target cell killing rate determination (MTS method)

[0147] The MHCI class I molecule-negative lymphoblastoid tumor cell line 721.221 was collected as target cells, fully resuspended into a single cell suspension, and 1×10 4The cell suspension was inoculated in a 96-well plate at a density of 10 cells / well, and cells or extracellular vesicles of different treatment groups were added, with 3 replicates per group. At the same time, an equal amount of PBS was set up to co-culture with tumor cells as a negative control well, and a blank control well containing only complete culture medium was set up, and co-cultured for 24 hours at 37°C and 5% CO2. After the co-culture, 40 μL MTS reagent (Promega, G3581) was added to each well and incubated for 4 hours at 37°C and 5% CO2. After the incubation, the 96-well plate was placed on a horizontal oscillator for 10 minutes to fully mix, and the absorbance was measured at 490 nm using an ELISA reader.

[0148] Target cell killing rate = (average absorbance value of PBS group - average absorbance value of treatment group) / (average absorbance value of PBS group - average absorbance value of blank control group).

[0149] (4) Detection of target cell apoptosis by flow cytometry

[0150] The Annexin V-FITC Apoptosis Detection Kit (Invitrogen, BMS500FI-300) was used as described in the instructions. After treating tumor cells 721.221 with different groups of NK cell extracellular vesicles, the tumor cells were washed once with PBS. Then, the tumor cells were incubated at 1×10 5 Resuspend the cells in 200 μL 1×Binding Buffer at a density of 10 cells / mL. Add 5 μL AnnexinV-FITC to 195 μL cell suspension, mix well and incubate at room temperature in the dark for 10 minutes. Wash the cells with 200 μL 1×Binding Buffer and resuspend the cells in 190 μL 1×Binding Buffer. Finally, add 10 μL Propidium Iodide and detect using BD Accuri C6 flow cytometer. Use Flowjo software (Version 10.4) to analyze the results.

[0151] (5) Statistical analysis

[0152] Statistical analysis was performed using GraphPadPrism software (Version 8.0.2). All mean values ​​were calculated from at least 3 independent experiments, and the data were expressed as mean ± standard deviation. Differences were analyzed using Student's t test. A p value of less than 0.05 was considered statistically significant.

[0153] 2 Experimental results

[0154] The present invention analyzes the changes in the killing effect of extracellular vesicles secreted by equal amounts of NK cells on tumor cells after knocking down NKG7 ( Fig. 9MTS assay showed that after knocking down NKG7, the killing effect of extracellular vesicles of equal amounts of NK cells on tumor cells was significantly reduced ( Fig. 9 B and C in Figure 1). Flow cytometry showed that after knocking down NKG7, apoptosis of tumor cells co-cultured with NK cell YTS and NK92MI extracellular vesicles was significantly reduced ( Fig. 9 D and E in

[0155] In order to exclude the influence of the number of extracellular vesicles and determine whether knocking down NKG7 affects the function of NK cell extracellular vesicles, the present invention further analyzed the changes in the killing effect of equal amounts of extracellular vesicles secreted by NK cells YTS and NK92MI on tumor cells after knocking down NKG7 ( Fig.10 A in the figure). The results of MTS detection showed that at different NK cell extracellular vesicle concentrations, after knocking down NKG7, the killing effect of NK cell extracellular vesicles on tumor cells was significantly reduced ( Fig.10 B in Figure 1). Flow cytometry results showed that at different NK cell extracellular vesicle concentrations, after knocking down NKG7, tumor cell apoptosis was significantly reduced ( Fig.10 The above results indicate that knocking down NKG7 not only reduces the secretion of NK cell extracellular vesicles, but also inhibits the tumor killing function of NK cell extracellular vesicles.

[0156] In addition, the present invention overexpressed NKG7 in the NK cell line YTS in which NKG7 was stably knocked down, and collected the NK extracellular vesicles secreted by the same amount of cells, and co-cultured with tumor cells 721.221. Compared with YTS cells in which NKG7 was knocked down, after overexpressing NKG7, the killing effect of NK extracellular vesicles on tumor cells was significantly increased ( Fig.11 A in Figure 1). Flow cytometry results showed that after overexpression of NKG7, apoptosis of tumor cells co-cultured with NK cell extracellular vesicles increased ( Fig.11 B and C). The results showed that overexpression of NKG7 promoted the killing effect of extracellular vesicles secreted by equal amounts of cells on tumor cells.

[0157] After overexpressing NKG7 in the NK cell line YTS with stable knockdown of NKG7, the present invention further collected an equal amount of extracellular vesicles and co-cultured them with tumor cells 721.221. At different concentrations of NK cell extracellular vesicles, the results of MTS cell viability assay showed that compared with YTS cells with knockdown of NKG7, after overexpressing NKG7, the killing effect of NK cell extracellular vesicles on tumor cells was significantly increased ( Fig.11 D in Figure 1). Flow cytometry results showed that after overexpression of NKG7, the apoptosis of tumor cells co-cultured with NK extracellular vesicles increased significantly at different concentrations of NK extracellular vesicles ( Fig.11E and F). The results showed that overexpression of NKG7 promoted the killing effect of equal amounts of extracellular vesicles on tumor cells.

[0158] 3 Experimental conclusions

[0159] The present invention finds that NKG7 promotes the killing effect of NK cell extracellular vesicles on tumor cells, proving that the killing effect of NK cells on tumors can be improved by increasing the expression of NKG7 in NK cells.

[0160] Example 9

[0161] In vivo experiments verified that NKG7 promoted the killing effect of NK cells on tumors

[0162] 1 Experimental methods

[0163] (1) Construction of subcutaneous transplanted tumor model in severely immunodeficient mice

[0164] Animal research was approved by the Biological and Medical Ethics Committee of Northeastern University (ethics approval number NEU-EC-2023A077S) before it was conducted. Twenty-four female severely immunodeficient NOG mice (NOD.Cg-Prkdcscid Il2rgtm1Sug / ShiJic, lacking T, B, and NK cells) aged 4 to 6 weeks were purchased from Beijing Weitong Lihua Company and raised in a special pathogen-free environment. After adaptive feeding, 3×10 6 721.221 tumor cells were injected into the armpits of mice. After palpable tumors appeared, the mice were randomly divided into 4 groups, with 6 mice in each group. In the negative control group, PBS was injected into the tumor of mice twice a week; in the control group, 1×10 7 The NK cell extracellular vesicles produced by YTS cells in the control group were injected into the tumor; experimental group 1 (equal amount of cells group): 1×10 7 NKG7 knockdown group NK cell extracellular vesicles produced by NK cells were injected into the tumor; Experimental group 2 (equal amount of extracellular vesicles group): 1×10 7 The NKG7 knockdown group and the NK extracellular vesicles produced by the NK cells of the control group were injected into the tumor intratumorally in an equal amount. The tumor volume was measured with a vernier caliper and the mice were weighed twice a week. According to the standards of the Animal Protection Committee of this center, all mice were killed by cervical dislocation 3 weeks after subcutaneous injection of tumor cells. The tumor size was recorded by photographing, and the differences in tumor size and growth curve of each group were statistically compared. The mouse tumor tissue was collected for the next step of hematoxylin-eosin (HE) staining and immunohistochemistry.

[0165] (2) Immunohistochemistry

[0166] See Example 1

[0167] (3) Statistical analysis

[0168] See Example 1

[0169] 2 Experimental results

[0170] In order to clarify whether NKG7 can promote the killing effect of NK extracellular vesicles on tumors in vivo, the present invention injected NK cell target cell 721.221 tumor cells into severely immunodeficient NOG mice subcutaneously. After the appearance of palpable tumors, three groups of differently treated NK extracellular vesicles or equal amounts of PBS were injected into the tumor twice a week. The treatment groups were: control group NK extracellular vesicles (shNC EVs), knockdown NKG7 group extracellular vesicles with the same amount of extracellular vesicles as the control group (shNKG7 EVs-equal amount of EVs), and knockdown NKG7 group extracellular vesicles secreted by the same amount of cells as the control group (shNKG7 EVs-equal amount of cells). After the experiment, the tumor burden of the mice was evaluated, and it was found that the volume and weight of the mouse tumors were in the following order from large to small: PBS treatment group>shNKG7 EVs-equal amount of cell treatment group>shNKG7 EVs-equal amount of EVs treatment group>shNC EVs treatment group ( Fig.12 B in Fig.12 C in the figure). The results show that after knocking down NKG7, the inhibitory effect of the same amount of NK cell extracellular vesicles on tumor cells is reduced. Due to the reduction in the number of extracellular vesicles, the inhibitory effect of the same amount of NK cell extracellular vesicles secreted by cells on tumor cells is further reduced after knocking down NKG7. Similarly, HE staining showed that compared with the control group, NK cell extracellular vesicles after knocking down NKG7 caused less tumor necrosis ( Fig.12 E in Figure 1). Immunohistochemistry results showed that after knocking down NKG7, the expression of CD31 in tumors treated with NK cell extracellular vesicles was higher, indicating that its inhibitory effect on angiogenesis was reduced ( Fig.12 F in Figure 3). The expression of Ki67, the tumor proliferation index, did not change significantly. This may be because the tumor cells are lymphoma cell lines, whose Ki67 expression is generally high, and no significant difference was observed ( Fig.12 The above results show that the in vivo experiment proves that the killing effect of equal amount of extracellular vesicles on tumor cells is reduced after NKG7 is knocked down in NK cells, and the killing effect of extracellular vesicles secreted by cells in the equal amount of NKG7 knockdown group on tumor cells is further reduced due to the reduction in number. NKG7 can promote the killing effect of NK cell extracellular vesicles on tumors in vivo.

[0171] 3 Experimental conclusions

[0172] The present invention finds that NKG7 in vivo can promote the killing effect of NK cell extracellular vesicles on tumors.

[0173] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creative work, and these embodiments all fall within the scope of protection of the present invention.

Claims

1. Use of reagents for detecting NKG7 in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy.

2. Use of reagents for detecting NKG7 in tumor tissue, soluble NKG7 in plasma and / or NKG7 in plasma exosomes in the preparation of a kit for predicting the efficacy and / or adverse reactions of tumor immunotherapy.

3. Use of a reagent for detecting soluble NKG7 in plasma in the preparation of a kit having any one or two or more of the functions described in ① to ③: ① Predict thyroid-related irAEs; ②Prediction of immune hypopituitarism; ③Predict grade II-III skin-related irAEs.

4. Use of reagents for detecting exosomal NKG7 in plasma in the preparation of kits for predicting cardiac-related irAEs and / or predicting grade III irAEs.

5. Use of a reagent for detecting the proportion of NKG7high CD8+T cells in peripheral blood and / or detecting the expression of NKG7 in NKG7high CD8+T cells in peripheral blood in the preparation of a kit for predicting tumor immune-related adverse reactions.

6. Use of a reagent for detecting the proportion of NKG7high CD8+T cells in peripheral blood and / or detecting the expression of NKG7 in NKG7high CD8+T cells in peripheral blood in the preparation of a kit having any one or more of the functions described in a to c: a. Prediction of immune myocarditis; b. Prediction of immune arthritis; c. Prediction of immune thyroiditis.

7. Use of reagents that overexpress NKG7 in the preparation of products that enhance the killing function of NK cells.

8. Application of reagents that overexpress NKG7 in the preparation of drugs for enhancing the efficacy of tumor immunotherapy.

9. The use according to any one of claims 1, 2, 5 or 8, characterized in that: The tumor includes a solid tumor.